- In February 2024, Telix Pharmaceuticals announced its agreement to acquire QSAM Biosciences, Inc. and its lead investigational drug, Samarium-153-DOTMP (153Sm-DOTMP). This acquisition allows Telix to enter an untapped market and expand its customer base by adding therapeutic radiopharmaceuticals for primary and metastatic bone cancer to its portfolio
- In October 2023, Zetagen Therapeutics published early clinical trial data on ZetaMet in the peer-reviewed journal Pain Management. The data highlighted the safety and efficacy of ZetaMet in treating patients with bone metastases
- In March 2023, researchers at the University of Sheffield and the University of East Anglia developed a new drug called CADD522 for treating primary bone cancers. Preclinical models showed a 50% increase in survival rates with this drug
- In December 2021, Zetagen Therapeutics received breakthrough device designation from the U.S. Food and Drug Administration's (FDA) Centers for Devices and Radiological Health (CDRH) for its ZetaMet technology. This designation validated the potential of ZetaMet as a novel treatment for metastatic bone lesions and expedited its development and review process
- In October 2020, Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals Inc., to expand its capabilities in treating various disorders, including infectious diseases, vaccines, neuroscience, bone cancer, and pulmonary hypertension
